Pharmstandard
 | |
| Public (OAO) | |
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | Dolgoprudny, Russia |
Key people |
Viktor Vladimirovich Kharitonin,(Chairman) Igor Konstantinovich Krylov, (CEO) |
| Products | Remedies |
| Revenue |
 US$ 1.6 billion (2012) |
| Profit |
US$ 321.1 million (2012) |
Number of employees | 5,001 |
| Website | pharmstd.com |
Pharmstandard is the leading Russian pharmaceutical company, it is headquartered in Dolgoprudny.
Pharmstandard portfolio includes over 200 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc. Over 90 products offered by Pharmstandard are included in the List of Vital Pharmaceutical Products.[1]
The company has six manufacturing facilities located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk and Tyumen.
Pharmstandard was delisted from the London and Moscow stock exchanges in 2017.[2]
References
- ↑ https://www.youtube.com/watch?v=tdTUwbhkPfc
- ↑ "BRIEF-Pharmstandard shares to be delisted as of March 24 - Moscow Exchange". Reuters. 17 February 2017. Retrieved 23 April 2017.
| |
|
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.